While the mechanism is plausible, the evidence does not yet exist to say what it does in people, at what dose, for what problem, or in which populations, especially in women
[11] [4] Preclinical studies have suggested that combining amylin receptor agonism with GLP-1based therapies produces greater reductions in food intake and body weight than either approach in isolation, and early clinical data from the CagriSema programme (cagrilintide combined with semaglutide) has provided some supporting evidence in humans
Typically, GHK-Cu is prepared in compounding pharmacies under USP sterile guidelines, and physicians prescribe it as a compounded peptide. Clinics emphasize that its use is experimental and off-label
Conservative dosing approach (GI-sensitive individuals) For those who need gentler escalation
As an injected medication, it can also cause pain, irritation, and redness around the injection site